Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MIS: Challenges in an Evolving Market

Executive Summary

Technology and techniques for minimally invasive surgery continue to evolve as medical device manufacturers and clinicians alike look for ways to further minimize the invasiveness, pain, and scarring associated with surgery. At the same time, the economy and health care reform have created challenges for medical device manufacturers. In response to these challenges, mannufacturers competing in the MIS market are developing new products and marketing strategies designed to ease both the economic and environmental impact for providers.

You may also be interested in...



Teleflex Bets Percutaneous Laparoscopy Will Be MIS Game Changer

Story and Podcast: Teleflex Medical launched in March a novel portfolio of miniaturized percutaneous surgical instruments that have the same functionality as full-sized laparoscopic instruments, but allow surgeons to access the abdominal cavity using trocar-less entry and much smaller incisions than those required in traditional laparoscopy. Teleflex execs say the technology is a game changer, and the company hopes percutaneous laparoscopy will become the standard of care for the 4 million laparoscopic procedures performed annually in the US.

Covidien’s Project ADOPT: Moving The Needle On MIS

In an interview with Medtech Insight, Michael Tarnoff, Covidien’s corporate chief medical officer, discusses how Covidien hopes to drive growth in the market for minimally invasive surgical products through Project ADOPT, the company’s latest strategy for increasing physician adoption of MIS.

Hernia Repair: No Simple Solution

Hernia repair is a staple of the general surgeon’s practice, with more than two million procedures performed annually worldwide. However, the procedure has proven problematic due to the mesh products used to repair the hernia defect and their potential to cause complications over time. At the Fifth International Hernia Congress, held recently in New York City, physicians debated the pros and cons of the many hernia repair mesh products that are now available. Although the general consensus at the meeting was there is no “ideal mesh,” mesh manufacturers continue to innovate in this field, offering a host of new products for this $500+ million market, including a variety of biologic meshes for complex repairs, synthetic meshes with biologic-like properties, fully resorbable meshes, and meshes with bacteriostatic properties.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel